These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 579188)

  • 41. [Results of clinical study of cytembena].
    Karev NI; Gorbunova VA; Gurevich BS; Koliadina PI; Monul FA
    Vopr Onkol; 1976; 22(10):84-5. PubMed ID: 1037040
    [No Abstract]   [Full Text] [Related]  

  • 42. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
    Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
    Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemotherapy of ovarian cancer: past and present.
    Young RC
    Semin Oncol; 1975 Sep; 2(3):267-76. PubMed ID: 827024
    [No Abstract]   [Full Text] [Related]  

  • 45. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
    Teeling M; Hayes Y; Fitzmaurice B; McGing P; Carney DN
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I clinical trial of methylene dimethane sulfonate.
    Smith DB; Fox BW; Thatcher N; Steward WP; Scarffe JH; Wagstaff J; Vezin R; Crowther D
    Cancer Treat Rep; 1987 Sep; 71(9):817-20. PubMed ID: 3621213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
    Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-dose cisplatin in hypertonic saline in refractory ovarian cancer.
    Ozols RF; Ostchega Y; Myers CE; Young RC
    J Clin Oncol; 1985 Sep; 3(9):1246-50. PubMed ID: 2993535
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination chemotherapy for alkylator-resistant ovarian carcinoma: a preliminary report of a Southwest Oncology Group trial.
    Alberts DS; Hilgers RD; Moon TE; Martimbeau PW; Rivkin S
    Cancer Treat Rep; 1979 Feb; 63(2):301-5. PubMed ID: 109200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.
    Sørensen P; Høyer M; Jakobsen A; Malmström H; Havsteen H; Bertelsen K
    Gynecol Oncol; 2001 Apr; 81(1):58-62. PubMed ID: 11277650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
    Bookman MA; Malmström H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ
    J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concomitant phase II studies of pyrazofurin and razoxane in alkylating agent-resistant cases of epithelial ovarian carcinoma.
    Edmonson JH; Decker DG; Malkasian GD; Webb MJ
    Cancer Treat Rep; 1981; 65(11-12):1127-9. PubMed ID: 7296557
    [No Abstract]   [Full Text] [Related]  

  • 54. A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer.
    Brown TD; Ettinger DS; Donehower RC
    J Clin Oncol; 1986 Aug; 4(8):1270-6. PubMed ID: 3525770
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
    J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.
    Kane R; Harvey H; Andrews T; Bernath A; Curry S; Dixon R; Gottlieb R; Kukrika M; Lipton A; Mortel R; Ricci J; White D
    Cancer Treat Rep; 1979 Feb; 63(2):307-9. PubMed ID: 109201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
    Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
    J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Peptichemio in pretreated patients with ovarian cancer.
    Paccagnella A; Tredese F; Salvagno L; Brandes A; Sileni VC; Daniele O; Fornasiero A; Fosser V; Nicoletto O; Maggino T
    Cancer Treat Rep; 1985 Jan; 69(1):17-20. PubMed ID: 3155650
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
    Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
    Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.